Institut de génétique moléculaire de Montpellier (IGMM)

Special dressing procedure required to enter the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This laboratory has a high level of biosecurity, allowing it to host experiments requiring containment for the use of level-3 pathogenic biological agents (viruses and bacteria).

Cell line samples being returned to liquid nitrogen for preservation at around -160 °C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Entry airlock for the P2 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology.

Fingerprint recognition for access to the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This laboratory has a high level of biosecurity, allowing it to host experiments requiring containment for the use of level-3 pathogenic biological agents (viruses and bacteria).

Special dressing procedure required to enter the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This laboratory has a high level of biosecurity, allowing it to host experiments requiring containment for the use of level-3 pathogenic biological agents (viruses and bacteria).

Opening the biosafety cabinet (BSC) in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Human cell cultures infected with HIV-1 being placed in an incubator in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Pipetting compounds active against the replication of HIV-1 in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Human cell cultures infected with HIV-1 being placed in an incubator in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Experiments in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Closing the biosafety cabinet (BSC) in the P3 laboratory at the CEMIPAI centre for the study of infectious diseases and anti-infective pharmacology. This is where tests are done to study the action of the molecule ABX464 on the cells of patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs.

Cell line samples being stored in liquid nitrogen, at around -160°C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Aliquots of cells being placed in a cryopreservation box for storage in liquid nitrogen at around -160°C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Cell line samples being returned to liquid nitrogen for preservation at around -160 °C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Newly seeded human cell cultures. They are then placed in an incubator so they continue to multiply. These cells will be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Cell line samples being returned to liquid nitrogen for preservation at around -160 °C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Cell line samples being returned to liquid nitrogen for preservation at around -160 °C. They will be used for various experiments in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Automatic inverted microscope for high-speed image acquisition and the observation of live cells. In this case, however, the cells infected with HIV (human immunodeficiency virus) are fixed, as they cannot be removed from the containment of the P3 laboratory while alive. Montpellier Ressources Imagerie (MRI) imaging platform.

Plate containing cell lines from a human carcinoma being inserted into an automatic inverted microscope, which allows high-speed image acquisition. These research scientists are interested in certain proteins with a view to understanding how they work on cell lines used as easily observable models. Afterwards, they will be able to transfer these observations to examine how the proteins interact with HIV (human immunodeficiency virus).

Observation of microscope images of cell lines from a human carcinoma produced using an automatic inverted microscope, which allows high-speed image acquisition. These research scientists are interested in certain proteins with a view to understanding how they work on cell lines used as easily observable models. Afterwards, they will be able to transfer these observations to examine how the proteins interact with HIV (human immunodeficiency virus).

Observation of microscope images of cell lines from a human carcinoma produced using an automatic inverted microscope, which allows high-speed image acquisition. The first three images correspond to the acquisition of each colour on a different channel, and the fourth is a reconstruction of the superimposed images with artificial colouring: the nucleus in blue, the protein of interest in green and the cytoplasm in red. These research scientists are interested in certain proteins with a view to…

Fluorescence optical microscope used to observe fixed cells. Here, the cells are human carcinoma cells (HeLa). These cells lines are used as models for research into HIV (human immunodeficiency virus).

Observation of human carcinoma cells (HeLa) using a fluorescence optical microscope. These cells lines are used as models for research into HIV (human immunodeficiency virus).

Dilutions of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). These dilutions are then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Discussion between Jamal Tazi and his collaborators about setting up an experiment. Jamal Tazi is a specialist in functional genomics and one of the winners of the 2017 CNRS Medal for Innovation.

Dilutions of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). These dilutions are then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Dilutions of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). These dilutions are then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Addition of a detection reagent for an ELISA (enzyme-linked immunosorbent assay) assay of the HIV-1 virus P24 protein. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Homogenisation, by pipetting, of the wells in an ELISA (enzyme-linked immunosorbent assay) assay of the HIV-1 virus P24 protein. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Homogenisation, by pipetting, of the wells in an ELISA (enzyme-linked immunosorbent assay) assay of the HIV-1 virus P24 protein. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Homogenisation, by pipetting, of the wells in an ELISA (enzyme-linked immunosorbent assay) assay of the HIV-1 virus P24 protein. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Pipetting a dilution of the molecule ABX464 used to inhibit HIV (human immunodeficiency virus). This dilution is then deposited on cells from patients infected with HIV. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Discussion between Jamal Tazi and his collaborators about setting up an experiment. Jamal Tazi is a specialist in functional genomics and one of the winners of the 2017 CNRS Medal for Innovation.

FACS (fluorescence-activated cell sorting) machine. This machine makes it possible to view the cells and analyse their specific surface markers by using fluorochrome-conjugated antibodies directed against the markers of interest. In this way, the cell types can be distinguished. The aim is to study the cell modifications that the molecule ABX464 could produce on the target cells by determining the expression of specific markers. This molecule is a drug candidate that can reduce virus reservoirs…

FACS (fluorescence-activated cell sorting) machine. This machine makes it possible to view the cells and analyse their specific surface markers by using fluorochrome-conjugated antibodies directed against the markers of interest. In this way, the cell types can be distinguished. The aim is to study the cell modifications that the molecule ABX464 could produce on the target cells by determining the expression of specific markers. This molecule is a drug candidate that can reduce virus reservoirs…

Human kidney cells, known as HEK 293T, observed using an inverted microscope (20x magnification). These cells, infectable with the chikungunya virus, are used in work on drug candidates. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Human kidney cells, known as HEK 293T, observed using an inverted microscope (20x magnification). These cells, infectable with the chikungunya virus, are used in work on drug candidates. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Human kidney cells, known as HEK 293T, observed using an inverted microscope (20x magnification). These cells, infectable with the chikungunya virus, are used in work on drug candidates. This photograph was taken in the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Human macrophages observed using an inverted microscope (20x magnification). They will be infected with HIV to test the action of ABX464. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Human macrophages observed using an inverted microscope (20x magnification). They will be infected with HIV to test the action of ABX464. The aim is to determine the effectiveness, in patients with chronic HIV, of the ABX464 molecule, a drug candidate that can reduce virus reservoirs. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Petri dish containing human cell cultures. They will be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Enzymatic digestion of cells using trypsin in order to detach those adhering to the culture dish and amplify them by seeding in new dishes. The aim is for these cells to divide and carry on multiplying. These human cells will then be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Cell count using trypan blue in a counting chamber. This method makes it possible to determine the concentration of the cell suspension (number of cells per millilitre of culture) and cell viability (percentage of live cells). These human cells will be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Enzymatic digestion of cells using trypsin in order to detach those adhering to the culture dish and amplify them by seeding in new dishes. The aim is for these cells to divide and carry on multiplying. These human cells will then be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).

Transfer of culture medium to be added to human cell cultures after seeding. These cells will then be used to amplify the chikungunya virus for work on drug candidates. This photograph was taken at the P2 platform of the CNRS-ABIVAX cooperative laboratory attached to the Institute of Molecular Genetics of Montpellier (IGMM).